Related Experiment Videos
Cause, treatment and outcome of patients with life-threatening haemoptysis
1Department of Medicine, National University Hospital, Singapore.
Background:
Massive haemoptysis is a life-threatening situation which requires immediate medical attention and intervention. We reviewed 23 patients with life-threatening haemoptysis to document the cause, describe the treatment of these patients and to determine which form of treatment had a better outcome.
Design:
Retrospective case study.
Methods:
Consecutive patients were reviewed and data collected for the underlying cause, treatment and outcome of patients with life-threatening haemoptysis.
Results:
Out of 23 patients, nine patients had active pulmonary tuberculosis and nine patients had post-tuberculous lung disease. Fifteen patients underwent bronchial embolisation, one patient had surgical resection and seven patients had received medical treatment. Five patients required intubation. Bronchial embolisation was significantly better than medical treatment at immediate cessation of haemoptysis (p < 0.05). Three (13%) patients died from haemoptysis. Follow-up duration averaged 16 months.
Conclusions:
The most common causes of haemoptysis were pulmonary tuberculosis and post-tuberculous bronchiectasis. Urgent bronchial artery embolisation was better at immediate cessation of haemoptysis than medical treatment.
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Flail Chest-II
Assessment:
1. Clinical Evaluation:
History:
Pulmonary Embolism III: Nursing Management
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...